Insulin Cost Caps and Pharmacoequity

The rising incidence of diabetes in the US, particularly affecting marginalized groups, highlights a pressing need for better management of the condition. Managing the skyrocketing costs of diabetes medications is crucial to reducing morbidity and ensuring equitable healthcare access. New proposals for insulin cost caps aim to address these financial barriers, which could significantly impact patients' ability to control their diabetes effectively. This move is vital in promoting pharmacoequity and improving health outcomes across diverse populations.